LifeMD price target raised to $14 from $13 at BTIG

BTIG raised the firm’s price target on LifeMD to $14 from $13 and keeps a Buy rating on the shares after hosting investor meetings with its management, stating that demand for meetings was high and sentiment continues to be positive. There is no slow-down in demand for GLP-1s, and the company’s healthcare business will likely turn break-even or profitable in the second half of the year, the analyst tells investors in a research note. LifeMD may also expand into new areas such as mental health, while the member-flow from Medifast is starting to pick up, the firm added.